Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Genus plc

GENSFPNK
Healthcare
Biotechnology
$37.25
$0.00(0.00%)
U.S. Market opens in NaNh NaNm

Genus plc Fundamental Analysis

Genus plc (GENSF) shows weak financial fundamentals with a PE ratio of 93.88, profit margin of 2.87%, and ROE of 3.89%. The company generates $0.7B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio0.09
Current Ratio1.94

Areas of Concern

ROE3.89%
Operating Margin6.30%
Cash Position1.96%
We analyze GENSF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 39.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
39.1/100

We analyze GENSF's fundamental strength across five key dimensions:

Efficiency Score

Weak

GENSF struggles to generate sufficient returns from assets.

ROA > 10%
2.15%

Valuation Score

Moderate

GENSF shows balanced valuation metrics.

PE < 25
93.88
PEG Ratio < 2
0.09

Growth Score

Moderate

GENSF shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

GENSF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.56
Current Ratio > 1
1.94

Profitability Score

Weak

GENSF struggles to sustain strong margins.

ROE > 15%
3.89%
Net Margin ≥ 15%
2.87%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is GENSF Expensive or Cheap?

P/E Ratio

GENSF trades at 93.88 times earnings. This suggests a premium valuation.

93.88

PEG Ratio

When adjusting for growth, GENSF's PEG of 0.09 indicates potential undervaluation.

0.09

Price to Book

The market values Genus plc at 3.81 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.81

EV/EBITDA

Enterprise value stands at 17.16 times EBITDA. This signals the market has high growth expectations.

17.16

How Well Does GENSF Make Money?

Net Profit Margin

For every $100 in sales, Genus plc keeps $2.87 as profit after all expenses.

2.87%

Operating Margin

Core operations generate 6.30 in profit for every $100 in revenue, before interest and taxes.

6.30%

ROE

Management delivers $3.89 in profit for every $100 of shareholder equity.

3.89%

ROA

Genus plc generates $2.15 in profit for every $100 in assets, demonstrating efficient asset deployment.

2.15%

Following the Money - Real Cash Generation

Operating Cash Flow

Genus plc generates limited operating cash flow of $67.71M, signaling weaker underlying cash strength.

$67.71M

Free Cash Flow

Genus plc produces free cash flow of $48.97M, offering steady but limited capital for shareholder returns and expansion.

$48.97M

FCF Per Share

Each share generates $0.74 in free cash annually.

$0.74

FCF Yield

GENSF converts 2.66% of its market value into free cash.

2.66%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

93.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.81

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.71

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.56

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.04

vs 25 benchmark

ROA

Return on assets percentage

0.02

vs 25 benchmark

ROCE

Return on capital employed

0.06

vs 25 benchmark

How GENSF Stacks Against Its Sector Peers

MetricGENSF ValueSector AveragePerformance
P/E Ratio93.8829.45 Worse (Expensive)
ROE3.89%779.00% Weak
Net Margin2.87%-24936.00% (disorted) Weak
Debt/Equity0.560.26 Weak (High Leverage)
Current Ratio1.944.65 Neutral
ROA2.15%-19344.00% (disorted) Weak

GENSF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Genus plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ